-
1
-
-
20344362911
-
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
-
Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005; 92: 1855-61.
-
(2005)
Br J Cancer
, vol.92
, pp. 1855-1861
-
-
Awada, A.1
Hendlisz, A.2
Gil, T.3
-
2
-
-
27144527372
-
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
-
Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005; 16: 1688-94.
-
(2005)
Ann Oncol
, vol.16
, pp. 1688-1694
-
-
Moore, M.1
Hirte, H.W.2
Siu, L.3
-
3
-
-
33744984843
-
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
-
Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2505-2512
-
-
Ratain, M.J.1
Eisen, T.2
Stadler, W.M.3
-
4
-
-
35548931472
-
Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results
-
Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5025.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5025
-
-
Szczylik, C.1
Demkow, T.2
Staehler, M.3
-
5
-
-
37549061995
-
A phase II trial of intrapatient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)
-
Amato RJ, Harris P, Dalton M, et al. A phase II trial of intrapatient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5026.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5026
-
-
Amato, R.J.1
Harris, P.2
Dalton, M.3
-
6
-
-
33846148701
-
Sorafenib in Advanced Clear-Call Renal-Cell Carcinoma
-
Escudier B, Eisen T, Stadler WM, et al. Sorafenib in Advanced Clear-Call Renal-Cell Carcinoma. N Engl J Med 2007; 356: 125-34.
-
(2007)
N Engl J Med
, vol.356
, pp. 125-134
-
-
Escudier, B.1
Eisen, T.2
Stadler, W.M.3
-
7
-
-
33846372076
-
Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib
-
Gondek K, Dhanda R, Simantov R, Gatzemeier U, Blumenschein GR, Reck M. Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. J Clin Oncol (Meeting Abstracts) 2006; 24: 17085.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 17085
-
-
Gondek, K.1
Dhanda, R.2
Simantov, R.3
Gatzemeier, U.4
Blumenschein, G.R.5
Reck, M.6
-
8
-
-
33644833910
-
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
-
Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
-
(2006)
J Clin Oncol
, vol.24
, pp. 16-24
-
-
Motzer, R.J.1
Michaelson, M.D.2
Redman, B.G.3
-
9
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516-24.
-
(2006)
JAMA
, vol.295
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
-
10
-
-
33750631676
-
Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC)
-
Rini BI, George DJ, Michaelson MD, et al. Efficacy and safety of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4522.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 4522
-
-
Rini, B.I.1
George, D.J.2
Michaelson, M.D.3
-
11
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
12
-
-
35548945277
-
Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC: Updated results
-
Srinivas S, Roigas J, Gillessen S, et al. Continuous daily administration of sunitinib in patients (pts) with cytokine-refractory metastatic renal cell carcinoma (mRCC: Updated results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5040.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5040
-
-
Srinivas, S.1
Roigas, J.2
Gillessen, S.3
-
14
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81.
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
15
-
-
33746651683
-
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
-
Amato RJ, Misellati A, Khan M, Chiang S. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2006; 24: 4530.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 4530
-
-
Amato, R.J.1
Misellati, A.2
Khan, M.3
Chiang, S.4
-
16
-
-
35548977012
-
A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
-
Jac J, Giessinger S, Khan M, Willis J, Chiang S, Amato R. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5107.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5107
-
-
Jac, J.1
Giessinger, S.2
Khan, M.3
Willis, J.4
Chiang, S.5
Amato, R.6
-
17
-
-
0042343801
-
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
-
Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.
-
(2003)
N Engl J Med
, vol.349
, pp. 427-434
-
-
Yang, J.C.1
Haworth, L.2
Sherry, R.M.3
-
18
-
-
35549006672
-
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-{alpha}2a vs placebo/interferon- {alpha}2a as firstline therapy in metastatic renal cell carcinoma
-
Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/ interferon-{alpha}2a vs placebo/interferon- {alpha}2a as firstline therapy in metastatic renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007; 25: 3.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 3
-
-
Escudier, B.1
Koralewski, P.2
Pluzanska, A.3
-
19
-
-
35548997095
-
Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)
-
Hutson TE, Davis ID, Machiels JP, et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). J Clin Oncol (Meeting Abstracts) 2007; 25: 5031.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5031
-
-
Hutson, T.E.1
Davis, I.D.2
Machiels, J.P.3
-
20
-
-
55849119731
-
-
Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2007; 25: 5093.
-
Sridhar SS, Hotte SJ, Mackenzie MJ, et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium. J Clin Oncol (Meeting Abstracts) 2007; 25: 5093.
-
-
-
-
21
-
-
35549007093
-
Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib
-
Rini BI, Wilding GT, Hudes G, et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. J Clin Oncol (Meeting Abstracts) 2007; 25: 5032.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5032
-
-
Rini, B.I.1
Wilding, G.T.2
Hudes, G.3
-
22
-
-
47249134321
-
Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI)
-
Stephenson J, Schreeder M, Waples J, et al. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol (Meeting Abstracts) 2007; 25: 15622.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 15622
-
-
Stephenson, J.1
Schreeder, M.2
Waples, J.3
-
23
-
-
33749257071
-
A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC patients (Pts)
-
Sosman JA, Flaherty K, Atkins MB, et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC patients (Pts). J Clin Oncol (Meeting Abstracts) 2006; 24: 3031.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 3031
-
-
Sosman, J.A.1
Flaherty, K.2
Atkins, M.B.3
-
24
-
-
34548229506
-
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
-
Ryan CW, Goldman BH, Lara PN, Jr., et al. Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-301.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3296-3301
-
-
Ryan, C.W.1
Goldman, B.H.2
Lara Jr., P.N.3
-
25
-
-
30944452354
-
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib
-
Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889-96.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7889-7896
-
-
Hainsworth, J.D.1
Sosman, J.A.2
Spigel, D.R.3
Edwards, D.L.4
Baughman, C.5
Greco, A.6
-
26
-
-
35548945707
-
Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
-
Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts) 2007; 25: 5099.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5099
-
-
Feldman, D.R.1
Kondagunta, G.V.2
Ronnen, E.A.3
-
27
-
-
36749098248
-
Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results
-
Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol (Meeting Abstracts) 2007; 25: 5034.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5034
-
-
Merchan, J.R.1
Liu, G.2
Fitch, T.3
-
28
-
-
41149152686
-
Phase I study of PTK787/ ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients
-
Speca JC, Mears AL, Creel PA, et al. Phase I study of PTK787/ ZK222584 (PTK/ZK) and RAD001 for patients with advanced solid tumors and dose expansion in renal cell carcinoma patients. J Clin Oncol (Meeting Abstracts) 2007; 25: 5039.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5039
-
-
Speca, J.C.1
Mears, A.L.2
Creel, P.A.3
-
29
-
-
33845571367
-
Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents
-
Tamaskar I, Shaheen P, Wood L, et al. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol (Meeting Abstracts) 2006; 24: 4597.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 4597
-
-
Tamaskar, I.1
Shaheen, P.2
Wood, L.3
-
30
-
-
35549008792
-
Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients
-
Sablin MP, Bouaita L, Balleyguier C, et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol (Meeting Abstracts) 2007; 25: 5038.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5038
-
-
Sablin, M.P.1
Bouaita, L.2
Balleyguier, C.3
-
31
-
-
36549059204
-
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
-
Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2007; 25: 5106.
-
(2007)
J Clin Oncol (Meeting Abstracts)
, vol.25
, pp. 5106
-
-
Dham, A.1
Dudek, A.Z.2
-
32
-
-
0034039255
-
Interferon in metastatic renal cell carcinoma
-
Fossa SD. Interferon in metastatic renal cell carcinoma. Semin Oncol 2000; 27: 187-93.
-
(2000)
Semin Oncol
, vol.27
, pp. 187-193
-
-
Fossa, S.D.1
-
33
-
-
7144227930
-
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie
-
Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338: 1272-8.
-
(1998)
N Engl J Med
, vol.338
, pp. 1272-1278
-
-
Negrier, S.1
Escudier, B.2
Lasset, C.3
-
34
-
-
3242814615
-
Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma
-
Fossa SD, Mickisch GH, De Mulder PH, et al. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004; 101: 533-40.
-
(2004)
Cancer
, vol.101
, pp. 533-540
-
-
Fossa, S.D.1
Mickisch, G.H.2
De Mulder, P.H.3
-
35
-
-
33845594648
-
A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo
-
Dhanda R, Gondek K, Song J, Cella D, Bukowski RM, Escudier B. A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol (Meeting Abstracts) 2006; 24: 4534.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 4534
-
-
Dhanda, R.1
Gondek, K.2
Song, J.3
Cella, D.4
Bukowski, R.M.5
Escudier, B.6
-
36
-
-
34547411610
-
Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma
-
Gao X, Reddy P, Dhanda R, et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2006; 24: 4604.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 4604
-
-
Gao, X.1
Reddy, P.2
Dhanda, R.3
-
37
-
-
2142695181
-
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
-
Atzpodien J, Kirchner H, Jonas U, et al. Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22: 1188-94.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1188-1194
-
-
Atzpodien, J.1
Kirchner, H.2
Jonas, U.3
|